Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients With Relapsed/Refractory Acute Myeloid Leukemia

Advances in Hematology - Egypt
doi 10.1155/2017/6464972
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Hindawi Limited

Related search

Cytarabine Dose for Acute Myeloid Leukemia

New England Journal of Medicine
Medicine
2011English

High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Leukemia Research
Cancer ResearchOncologyHematology
2011English

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

A Phase I Trial of Ribavirin and Low-Dose Cytarabine for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia With Elevated eIF4E

Haematologica
Hematology
2014English

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Hematology International
2019English

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Salvage Treatment for Refractory or Relapsed Acute Myeloid Leukemia: A 10-Year Single-Center Experience

Clinics
Medicine
2020English

A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2018English

A Randomized Trial of High-Versus Conventional-Dose Cytarabine in Consolidation Chemotherapy for Adult De Novo Acute Myeloid Leukemia in First Remission After Induction Therapy Containing High-Dose Cytarabine

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy